MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 300230 | Name: Blonanserin
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Blonanserin (Lonasen) is a relatively new atypical antipsychotic commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms and excessive sedation and hypotension.

Chemical Structure

Blonanserin
Blonanserin
CAS#132810-10-7 (free base)

Theoretical Analysis

MedKoo Cat#: 300230

Name: Blonanserin

CAS#: 132810-10-7 (free base)

Chemical Formula: C23H30FN3

Exact Mass: 367.2424

Molecular Weight: 367.50

Elemental Analysis: C, 75.17; H, 8.23; F, 5.17; N, 11.43

Price and Availability

Size Price Availability Quantity
25mg USD 350.00 2 Weeks
100mg USD 650.00 2 Weeks
250mg USD 1,050.00 2 Weeks
1g USD 2,950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
132812-45-4 (HCl) 132810-10-7 (free base) 132812-47-6 (citrate)
Synonym
Blonanserin; Lonasen;
IUPAC/Chemical Name
2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine.
InChi Key
XVGOZDAJGBALKS-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3
SMILES Code
FC1=CC=C(C2=C(CCCCCC3)C3=NC(N4CCN(CC)CC4)=C2)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO (10 mg/mmL)
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 367.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Murasaki M, Inoue Y, Nakamura H, Kinoshita T. Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies. Ann Gen Psychiatry. 2021 Sep 7;20(1):41. doi: 10.1186/s12991-021-00361-3. PMID: 34493318; PMCID: PMC8425119. 2: Kishi T, Matsuda Y, Nakamura H, Iwata N. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatr Res. 2013 Feb;47(2):149-54. doi: 10.1016/j.jpsychires.2012.10.011. Epub 2012 Nov 3. Erratum in: J Psychiatr Res. 2013 Oct;47(10):1545. PMID: 23131856. 3: Tenjin T, Miyamoto S. [Blonanserin in the treatment of schizophrenia]. Nihon Rinsho. 2013 Apr;71(4):660-5. Japanese. PMID: 23678596. 4: Deeks ED, Keating GM. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs. 2010 Jan;24(1):65-84. doi: 10.2165/11202620-000000000-00000. PMID: 20030420. 5: Andrade C, Harshe D, Tharayil HM, Tekkalaki B. Blonanserin patch for schizophrenia. Schizophr Res. 2020 Jan;215:445. doi: 10.1016/j.schres.2019.10.042. Epub 2019 Oct 31. PMID: 31676172. 6: Tsuchiya N, Okamoto K, Nakao S, Ohmori S, Shimizu T. Effect of Blonanserin on the Proliferation and Migration of Glioblastoma Cells. Pharmazie. 2023 May 1;78(5):37-41. doi: 10.1691/ph.2023.1821. PMID: 37189270. 7: Inoue Y, Tsuchimori K, Nakamura H. Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances. J Pharmacol Sci. 2021 Jan;145(1):42-51. doi: 10.1016/j.jphs.2020.09.006. Epub 2020 Oct 8. PMID: 33357778. 8: Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU. Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics. Clin Neuropharmacol. 2013 Nov-Dec;36(6):223-38. doi: 10.1097/WNF.0b013e3182aa38c4. PMID: 24201235. 9: Iwata N, Ishigooka J, Kim WH, Yoon BH, Lin SK, Sulaiman AH, Cosca R, Wang L, Suchkov Y, Agarkov A, Watabe K, Matsui T, Sato T, Inoue Y, Higuchi T, Correll CU, Kane JM. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study. Schizophr Res. 2020 Jan;215:408-415. doi: 10.1016/j.schres.2019.07.055. Epub 2019 Aug 27. PMID: 31471246. 10: Blonanserin. AD 5423. Drugs R D. 1999 Jul;2(1):49-50. doi: 10.2165/00126839-199902010-00014. PMID: 10610294. 11: Min A, Kim D. Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases. Clin Psychopharmacol Neurosci. 2013 Dec;11(3):165-7. doi: 10.9758/cpn.2013.11.3.165. Epub 2013 Dec 24. PMID: 24465254; PMCID: PMC3897766. 12: Nishitani N, Sasamori H, Ohmura Y, Yoshida T, Yoshioka M. Blonanserin suppresses impulsive action in rats. J Pharmacol Sci. 2019 Nov;141(3):127-130. doi: 10.1016/j.jphs.2019.09.013. Epub 2019 Oct 21. PMID: 31690490. 13: Saito T, Sugimoto S, Sakaguchi R, Nakamura H, Ishigooka J. Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. J Child Adolesc Psychopharmacol. 2022 Feb;32(1):12-23. doi: 10.1089/cap.2021.0013. Epub 2022 Feb 8. PMID: 35133884; PMCID: PMC8884167. 14: Sakai S, Morimoto Y, Matsuzaka Y, Nakano T, Kanegae S, Imamura A, Ozawa H. Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report. Neuropsychopharmacol Rep. 2021 Sep;41(3):440-443. doi: 10.1002/npr2.12200. Epub 2021 Aug 6. PMID: 34357702; PMCID: PMC8411311. 15: Ohi K, Takai K, Kuramitsu A, Sugiyama S, Shioiri T. Switching from blonanserin oral tablets/powders to transdermal patches alleviates extrapyramidal symptoms in patients with schizophrenia: A 52-week open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2022 Mar 8;113:110470. doi: 10.1016/j.pnpbp.2021.110470. Epub 2021 Nov 3. PMID: 34740708. 16: Baba S, Enomoto T, Horisawa T, Hashimoto T, Ono M. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range. J Pharmacol Sci. 2015 Mar;127(3):326-31. doi: 10.1016/j.jphs.2015.01.007. Epub 2015 Feb 7. PMID: 25837930. 17: Wen YG, Ni XJ, Zhang M, Liu X, Shang DW. Simultaneous determination of blonanserin and its metabolite in human plasma and urine by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Aug 15;903:46-52. doi: 10.1016/j.jchromb.2012.06.037. Epub 2012 Jul 4. PMID: 22818206. 18: Tenjin T, Miyamoto S, Ninomiya Y, Kitajima R, Ogino S, Miyake N, Yamaguchi N. Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2013;9:587-94. doi: 10.2147/NDT.S34433. Epub 2013 Apr 29. PMID: 23766647; PMCID: PMC3677929. 19: Harvey PD, Nakamura H, Miura S. Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study. Neuropsychopharmacol Rep. 2020 Mar;40(1):63-72. doi: 10.1002/npr2.12089. Epub 2019 Dec 1. PMID: 31788985; PMCID: PMC7292214. 20: Nishibe H, Tateno A, Sakayori T, Yamamoto M, Kim W, Kakuyama H, Okubo Y. Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia. Int J Neuropsychopharmacol. 2021 Feb 15;24(2):108-117. doi: 10.1093/ijnp/pyaa071. PMID: 32936897; PMCID: PMC7883894.